SODIUM THIOSULFATE

Peak

sodium thiosulfate

NDAINTRAVENOUSSOLUTION
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6

Clinical Trials (5)

NCT04983238Phase 1/2Completed

Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985

Started Jan 2022
NCT00983398Phase 1/2Unknown

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

Started Jul 2009
17 enrolled
Central Nervous System Embryonal NeoplasmEmbryonal Tumor With Multilayered Rosettes, C19MC-AlteredGerm Cell Tumor+7 more
NCT00568399N/ACompleted

Sodium Thiosulfate Treatment of Vascular Calcification in ESRD

Started Dec 2007
48 enrolled
Complication of HemodialysisCardiovascular Diseases
NCT00303849Phase 1/2Completed

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Started Sep 2005
33 enrolled
Anaplastic OligoastrocytomaAnaplastic OligodendrogliomaMixed Glioma+1 more
NCT00238173Phase 1Terminated

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Started Dec 2004
2 enrolled
Bone Marrow SuppressionBrain and Central Nervous System TumorsDrug/Agent Toxicity by Tissue/Organ+1 more

Loss of Exclusivity

LOE Date
Mar 29, 2031
61 months away
Patent Expiry
Mar 29, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
11753301
Feb 10, 2030
SubstanceProduct
U-3682
12304813
Feb 10, 2030
Product
10479686
Jul 7, 2030
Product
U-3390
9345724
Jul 7, 2030
SubstanceProduct
U-2015
9585912
Jul 7, 2030
SubstanceProduct